Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
EXS-617 by Exscientia for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
EXS-617 is under clinical development by Exscientia and currently in Phase II for Head And Neck Squamous Cell Carcinoma (HNSC)....
Data Insights
EXS-617 by Exscientia for Epithelial Ovarian Cancer: Likelihood of Approval
EXS-617 is under clinical development by Exscientia and currently in Phase II for Epithelial Ovarian Cancer. According to GlobalData, Phase...